Eli Lilly | LLY - Debt


Eli Lilly reported $42.5B in Debt for its fiscal quarter ending in December of 2025.





Debt Change Date
AbbVie USD 67.5B 67.5B Dec/2025
Abbott USD 13.86B 919M Dec/2025
ALKERMES USD 1.58B 1.51B Mar/2026
Amgen USD 54.6B 17M Dec/2025
AstraZeneca USD 33.92B 4.3B Mar/2026
Baxter International USD 9.78B 68M Dec/2025
Biogen USD 6.56B 275.1M Mar/2026
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Drreddys Laboratories INR 67.73B 19.09B Dec/2025
Eli Lilly USD 42.5B 3.6M Dec/2025
Gilead Sciences USD 24.94B 5M Dec/2025
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Glaxosmithkline GBP 17.75B 396M Sep/2025
J&J USD 47.93B 2.14B Dec/2025
Medtronic USD 28.07B 1.03B Dec/2025
Merck USD 49.34B 7.97B Dec/2025
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novartis USD 47B 11.62B Mar/2026
Novartis USD 32.02B 615M Sep/2025
Novo Nordisk DKK 118.72B 61.75B Mar/2025
Perrigo USD 3.64B 4.5M Dec/2025
Pfizer USD 63.73B 231M Mar/2026
Phibro Animal Health USD 474.17M 730K Sep/2024
Prestige Brands USD 1.08B 38.27M Dec/2025
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sanofi EUR 20.33B 1.43B Dec/2025
Sanofi EUR 21.76B 530M Sep/2025
United Therapeutics USD 200M 100M Mar/2025
Zoetis USD 9.24B 1.96B Dec/2025